OptimizeRx (NasdaqCM:OPRX) opened 2026 with Q1 revenue of US$19.8 million and a reported loss of US$0.5 million, or EPS of US$0.03, setting a more muted tone after a profitable 2025. The company has seen quarterly revenue move from US$21.9 million in Q1 2025 to US$19.8 million in Q1 2026. EPS shifted from a loss of US$0.12 to a smaller loss of US$0.03 as trailing 12 month EPS reached US$0.37. With margins now positive on a trailing 12 month basis and near break even in the latest quarter, the focus for investors is on how durable that margin profile looks relative to the company’s growth runway.

See our full analysis for OptimizeRx.

With the headline numbers on the table, the next step is to see how this earnings release lines up with the prevailing stories around OptimizeRx, highlighting where the data supports those narratives and where it pushes back.

Margins Look Different Over 12 Months Than In Single Quarter

• On a trailing 12 month basis, OptimizeRx earned US$6.8 million of net income and US$0.37 in EPS, compared with a loss of US$0.5 million and EPS of US$0.03 in Q1 2026 alone. This means the quarter sits inside a much stronger full year picture.
• Consensus narrative expects revenue to grow about 4.9% a year with margins rising from 4.7% to 9.3%. Yet the latest quarter shows revenue of US$19.8 million against US$107.3 million for the trailing 12 months, which means you are comparing one softer quarter against a year where margins were solidly positive.
  • Consensus narrative points to earnings reaching US$11.7 million by around 2029, while trailing 12 month net income is US$6.8 million. On that basis, the company is already more than halfway to that earnings level on historical data.
  • At the same time, the modest 3.2% trailing revenue growth rate is below the 11.6% US market figure that the analysis references. As a result, the margin story is stronger than the top line growth story right now.

P/E Of 13.5x And DCF Fair Value Of US$51.95

• The stock trades on a trailing P/E of 13.5x compared with a Global Healthcare Services average of 26x and a peer average of 47.1x. The current share price of US$4.92 sits far below the DCF fair value of US$51.95, which indicates a very large gap between the market price and that model.
• Bulls argue the company could justify a higher valuation as recurring and higher margin revenue builds, and the current numbers give that view mixed support.
  • Trailing 12 month net profit of US$6.8 million and positive EPS of US$0.37 show the move into profitability that bullish investors look for. This lines up with the idea of improved earnings quality.
  • However, the same data set shows trailing revenue growth at only 3.2% a year, which is below the 11.6% US market reference. Any re rating that bulls anticipate would therefore likely depend on stronger revenue growth than what is in the trailing figures.

Bulls argue this profitability turn could be the base for a much bigger story if growth picks up from here, and the detailed bullish case sets out how that might look over time. 🐂 OptimizeRx Bull Case

Slow Revenue Growth Backs Parts Of The Bear Case

• Trailing revenue is growing at about 3.2% a year and earnings are expected to grow about 3.5% a year, both below the 11.6% and 16.8% growth figures cited for the wider US market. The company is therefore currently growing more slowly than those reference points despite having just moved into profit.
• Bears highlight that regulatory pressure, client concentration and more competition could keep growth muted, and the data gives some backing to that concern.
  • The modest trailing growth rates mean that even with a P/E of 13.5x and positive earnings, the stock does not yet show the kind of rapid revenue expansion that would quickly close the gap with the US$51.95 DCF fair value.
  • Forecast earnings growth of about 3.5% a year being below the 16.8% broader market figure in the analysis is consistent with the cautious view that, without faster adoption or new products, earnings could track behind broader healthcare and market benchmarks.

Skeptics point to these slower growth figures as evidence that the current profitability may not automatically translate into outsized long term returns without a shift in the growth profile. 🐻 OptimizeRx Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for OptimizeRx on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With the mixed signals in this update, it makes sense to look past the headlines, review the underlying numbers, and decide how convincing the rewards really are. If you want a clear summary of the positive factors identified so far, start with the 3 key rewards.

See What Else Is Out There

OptimizeRx currently pairs a low P/E and positive earnings with relatively modest 3.2% trailing revenue growth and forecast earnings growth of about 3.5% a year.

If you want ideas that pair stronger growth potential with quality fundamentals, check out the screener containing 23 high quality undiscovered gems today to broaden your watchlist quickly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.